Cytomx Therapeutics Inc buy melinda
Start price
30.08.18
/
50%
€20.66
Target price
30.08.19
€23.27
Performance (%)
-61.09%
End price
30.08.19
€8.04
Summary
This prediction ended on 30.08.19 with a price of €8.04. Massive losses of -61.09% were the result for the BUY prediction by melinda. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Cytomx Therapeutics Inc | -4.580% | -4.580% | 5.634% | -80.880% |
| iShares Core DAX® | 2.594% | -1.158% | 14.782% | 16.813% |
| iShares Nasdaq 100 | 3.553% | -1.727% | 43.265% | 44.227% |
| iShares Nikkei 225® | 0.687% | -8.354% | 18.454% | 1.361% |
| iShares S&P 500 | 2.209% | -0.942% | 31.361% | 42.812% |
Comments by melinda for this prediction
In the thread Cytomx Therapeutics Inc diskutieren
SecteurRecherche biotechnologique et médicale Agenda 26/11 Publication de résultats
Operates as an oncology-base biopharmaceutical company, which focuses on developing probody therapeutics for the treatment of cancer
CytomX Therapeutics, Inc. engages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform.
Its pipeline includes immunotherapies, probody drug conjugates, T cell engaging bispecifics, and other multiple programs.
The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.
CytomX Therapeutics, Inc. engages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform.
Its pipeline includes immunotherapies, probody drug conjugates, T cell engaging bispecifics, and other multiple programs.
The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.
Nombre d'employés : 92 personnes.
(Laufzeit überschritten)
Stopped prediction by melinda for Cytomx Therapeutics Inc
Cytomx Therapeutics Inc
Start price
Target price
Perf. (%)
€6.80
29.09.19
29.09.19
€13.00
04.11.21
04.11.21
-19.71%
01.07.21
01.07.21
Cytomx Therapeutics Inc
Start price
Target price
Perf. (%)
€30.70
08.03.18
08.03.18
€36.08
19.03.18
19.03.18
0.38%
19.03.18
19.03.18
Cytomx Therapeutics Inc
Start price
Target price
Perf. (%)
€17.68
20.03.17
20.03.17
€15.33
20.03.17
20.03.17
-3.83%
20.03.17
20.03.17